Pomalidomide-PEG5-CO2H

Background Introduction

Pomalidomide-PEG5-CO2H is a versatile E3 ligase ligand-linker conjugate designed for use in targeted protein degradation research. As a derivative of pomalidomide, an immunomodulatory drug (IMiD), this molecule incorporates a polyethylene glycol (PEG5) linker and a carboxylic acid functional group (CO2H), enabling convenient conjugation to various target binders. Due to its optimized design and favorable physicochemical properties, Pomalidomide-PEG5-CO2H is widely utilized in the development of novel Proteolysis Targeting Chimeras (PROTACs).

Mechanism

Pomalidomide-PEG5-CO2H functions by recruiting the E3 ligase cereblon (CRBN) through the pomalidomide moiety. The PEG5 chain provides flexibility and optimal spatial arrangement between the E3 ligase ligand and the attached target protein ligand via the carboxylic acid handle. Upon conjugation to a target binder, the resulting PROTAC molecule simultaneously brings the target protein and CRBN into close proximity, initiating ubiquitination of the target protein. This process directs the protein to the proteasome for selective degradation, facilitating targeted protein knockdown at the post-translational level.

Applications

Pomalidomide-PEG5-CO2H is ideal for constructing custom PROTACs for targeted protein degradation in cellular and in vivo studies. Its optimized linker and functional group allow for straightforward conjugation chemistry, making it suitable for medicinal chemistry, drug discovery, and mechanism-of-action studies. Researchers use Pomalidomide-PEG5-CO2H to design PROTAC molecules to degrade disease-related or aberrant proteins, offering new therapeutic strategies for oncology, neurology, immunology, and beyond. This conjugate is a valuable tool for accelerating the development of next-generation small-molecule degraders.

• PEG5 linker improves water solubility and pharmacokinetic properties for enhanced bioavailability in PROTAC development.
• Carboxylic acid terminus facilitates efficient conjugation to target protein ligands, streamlining synthesis of CRBN-based PROTACs.

Pomalidomide-PEG5-CO2H is a versatile E3 Ligase Ligand-Linker Conjugate used in PROTACs for targeted protein degradation. This molecule integrates a pomalidomide-based ligand with a polyethylene glycol linker, offering flexibility and hydrophilicity, thus enhancing solubility and cellular permeability. The following provides a detailed description of this molecule, including its linker, ligand, and reactive site characteristics.

Linker: The linker in Pomalidomide-PEG5-CO2H is a polyethylene glycol (PEG) chain consisting of five ethylene glycol units. This provides moderate flexibility and hydrophilicity, enhancing solubility and cellular permeability. The linker is non-cleavable, ensuring stability during the degradation process.

Ligand: The ligand is derived from pomalidomide, a thalidomide analog known for its high affinity to the cereblon E3 ubiquitin ligase. Its structural characteristics facilitate the recruitment of the E3 ligase complex, which is crucial for effective protein degradation.

Reactive Site: The carboxylic acid group at the terminus of the PEG5 linker acts as the reactive site for coupling with the target protein ligand. Recommended reaction types include amide bond formation through carbodiimide coupling, providing a stable and efficient conjugation.

Recommended Target Protein Ligand: The molecule is compatible with amine-containing warheads, which can form stable amide bonds with the carboxylic acid terminus. This compatibility allows for the development of PROTACs targeting proteins with accessible lysine residues, facilitating research in protein degradation pathways and the study of disease-related proteins.